Drug-induced gingival overgrowth: FAERS based real-world pharmacovigilance study and network pharmacology analysis
Frontiers in Pharmacology · 02.04.2026 · 17
DOI: 10.3389/fphar.2026.1775430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.04.2026. Verfasst von Qingxia Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Drug-induced gingival overgrowth (DIGO) as an interdisciplinary clinical challenge, faces dual therapeutic barriers due to its unclear pathogenesis and high recurrence rate, forcing clinicians to balance therapeutic benefits against oral complications. Analyzing drug-adverse reaction links via real-world evidence can shift treatment from passive intervention to proactive prevention. This study aimed to identify DIGO-associated drugs using the US Food and Drug Association Adverse Event Reporting System (FAERS) data and to validate signals through pharmacology-guided multivariate logistic regression, thereby improving signal robustness and clinical interpretability.
Methods
FAERS data (2004Q1–2024Q4) were analyzed. Multiple disproportionality methods including reporting odds ratios (RORs), proportional reporting ratios (PRRs), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) were employed for signal detection, with Fisher’s exact test and false discovery rate (FDR) correction applied to control for multiple testing. Positive signals were subsequently validated through multivariate logistic regression and time-to-onset (TTO) analysis. Network pharmacology incorporating Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses to delineate underlying molecular pathways.
Results
Among 22,375,298 reports, 1,835 cases of gingival hyperplasia and 11,145 gingival lesions were identified. Bisphosphonates, alongside calcium-channel blockers (CCBs), immunosuppressants (IMMs), and antiepileptics (AEPs), showed significant associations (p < 0.0001). Zoledronic acid (ROR = 3.23, 95% CI: 2.24–4.67) and pamidronate (ROR = 5.33, 95% CI: 2.8–9.92) showed strong signals. TTO analysis indicated prolonged bisphosphonate use increased DIGO risk. Network analysis suggested possible involvement of Phosphatidylinositol 3-Kinase/A Kinase T (PI3K-AKT) and Mitogen-Activated Protein Kinase (MAPK).
Conclusion
CCBs carried the highest DIGO risk, followed by IMMs and AEPs. Bisphosphonates were associated with DIGO and may act through PI3K-AKT/MAPK pathways, providing a mechanistic hypothesis for clinical medication safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- College of Clinical Pharmacy, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Pediatric infectious, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Zhu, Q., Wu, Z., Jiao, X., Han, L., & Yuan, Y. (2026). Drug-induced gingival overgrowth: FAERS based real-world pharmacovigilance study and network pharmacology analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1775430
Vancouver
Zhu Q, Wu Z, Jiao X, Han L, Yuan Y. Drug-induced gingival overgrowth: FAERS based real-world pharmacovigilance study and network pharmacology analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1775430
BibTeX
@article{Zhu2026,
author = {Zhu, Qingxia and Wu, Zebing and Jiao, Xianting and Han, Lu and Yuan, Yongfang},
title = {Drug-induced gingival overgrowth: FAERS based real-world pharmacovigilance study and network pharmacology analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1775430}
}
EUVIMED